Jeffrey Gelfand, MD

Neurologist

Dr. Jeffrey Gelfand is a neurologist who specializes in caring for patients with a wide range of autoimmune, inflammatory and neurodegenerative neurological disorders. This includes multiple sclerosis (MS), neurosarcoidosis, encephalitis, meningitis, transverse myelitis, optic neuritis, neuromyelitis optica, central nervous system vasculitis, autoimmune dementias and encephalopathies, autoimmune cerebellar ataxia, and paraneoplastic neurological syndromes. He also treats neurological problems in people with rheumatological and other systemic inflammatory or medical illnesses.

Gelfand received his medical degree from Harvard Medical School. He then completed an internship in internal medicine, a residency in neurology and fellowship training in multiple sclerosis and neuroimmunology, all at UCSF. Gelfand went on to earn a master's degree in advanced study in clinical research at UCSF.

As director of the Multiple Sclerosis Center's Clinical Fellowship Training Program at UCSF, Gelfand trains specialists in multiple sclerosis and neuroimmunology after their neurology residency. Gelfand received the Robert B. Layzer teaching award in 2014 and an Excellence in Teaching Award from the UCSF Haile T. Debas Academy of Medical Educators in 2015.

Gelfand was elected as a fellow of the American Academy of Neurology and serves as a member of the organization's clinical research subcommittee. In 2016, Gelfand chaired the American Neurological Association's autoimmune neurology special interest group.

Gelfand is an assistant professor of clinical neurology at UCSF.

Clinics

Memory and Aging Center
1500 Owens St., Suite 320
San Francisco, CA 94158
Phone: (415) 353-2057
Fax: (415) 353-8292

Hours: Monday to Friday
8 a.m. – 5 p.m.

Multiple Sclerosis Center
1500 Owens St., Suite 320
San Francisco, CA 94158
Phone: (415) 353-2069
Fax: (415) 353-2633

Hours: Monday to Friday
8 a.m. – 5 p.m.

Board Certification

Neurology

More about Jeffrey Gelfand

Education

Harvard School of Medicine 2006
UCSF, Masters in Advanced Study in Clinical Research 2013

Residencies

UCSF Medical Center, Neurology 2010

Fellowships

UCSF Medical Center, Multiple Sclerosis and Neuroimmunology 2011

Selected Research and Publications

  1. Damotte V, Lizée A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, Gomez R, Lincoln R, Tang W, Chen T, Lee N, Villoslada P, Hollenbach JA, Bevan CD, Graves J, Bove R, Goodin DS, Green AJ, Baranzini SE, Cree BA, Henry RG, Hauser SL, Gelfand JM, Gourraud PA. Harnessing electronic medical records to advance research on multiple sclerosis. Mult Scler. 2018 Jan 01; 1352458517747407.
  2. Baud MO, Vitt JR, Robbins NM, Wabl R, Wilson MR, Chow FC, Gelfand JM, Josephson SA, Miller S. Pleocytosis is not fully responsible for low CSF glucose in meningitis. Neurol Neuroimmunol Neuroinflamm. 2018 Jan; 5(1):e425.
  3. Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, Farooque P, Gelfand JM, Geschwind MD, Hirsch LJ, Somerville E, Lang B, Vincent A, Leite MI, Waters P, Irani SR. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2017 Dec 18.
  4. Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, Koth LL, Hauser SL, Dierkhising J, Vu N, Sriram S, Moses H, Bagnato F, Kaufmann JA, Ammah DJ, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S. Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series. Neurology. 2017 Oct 13.
  5. Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, Nobuta H, Zhu A, Friessen M, Gerona R, von Büdingen HC, Henry RG, Hauser SL, Chan JR. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017 Oct 10.
  6. Gelfand JM. Demystifying Neurosarcoidosis and Informing Prognosis. JAMA Neurol. 2017 Oct 09.
  7. Tremblay MA, Villanueva-Meyer JE, Cha S, Tihan T, Gelfand JM. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions. J Neurol Sci. 2017 Oct 15; 381:83-87.
  8. Benn BS, Lehman Z, Kidd SA, Ho M, Sun S, Ramstein J, Arger NK, Nguyen CP, Su R, Gomez A, Gelfand JM, Koth LL. Clinical and Biological Insights from the University of California San Francisco Prospective and Longitudinal Cohort. Lung. 2017 Jul 13.
  9. Gelfand JM, Cree BAC, Hauser SL. Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis. Neurotherapeutics. 2017 Jul 10.
  10. Ward ME, Chen R, Huang HY, Ludwig C, Telpoukhovskaia M, Taubes A, Boudin H, Minami SS, Reichert M, Albrecht P, Gelfand JM, Cruz-Herranz A, Cordano C, Alavi MV, Leslie S, Seeley WW, Miller BL, Bigio E, Mesulam MM, Bogyo MS, Mackenzie IR, Staropoli JF, Cotman SL, Huang EJ, Gan L, Green AJ. Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Sci Transl Med. 2017 Apr 12; 9(385).
  11. Karageorgiou, E., Naasan, G., Pleasure, S.J., Alexandrescu, S., Gelfand, J.M., Tammewar, G., Miller, B.L., Rabinovici, G.D. and Grinberg, L.T., . Focal cerebral -amyloid angiopathy A distinct clinicopathologic presentation. Neurology: Clinical Practice. 2017.
  12. Gelfand JM. Risk of Multiple Sclerosis After a Clinically Isolated Syndrome: From Magnetic Resonance Imaging to Oligoclonal Bands to Activated T Cells. JAMA Neurol. 2017 Mar 01; 74(3):262-263.
  13. Casaletto KB, Ward ME, Baker NS, Bettcher BM, Gelfand JM, Li Y, Chen R, Dutt S, Miller B, Kramer JH, Green AJ. Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults. Neurobiol Aging. 2017 Mar; 51:141-147.
  14. Block VJ, Lize A, Crabtree-Hartman E, Bevan CJ, Graves JS, Bove R, Green AJ, Nourbakhsh B, Tremblay M, Gourraud PA, Ng MY, Pletcher MJ, Olgin JE, Marcus GM, Allen DD, Cree BA, Gelfand JM. Continuous daily assessment of multiple sclerosis disability using remote step count monitoring. J Neurol. 2017 Feb; 264(2):316-326.
  15. Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Bdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016 Oct; 80(4):499-510.
  16. Miloslavsky EM, Naden RP, Bijlsma JW, Brogan PA, Brown ES, Brunetta P, Buttgereit F, Choi HK, DiCaire JF, Gelfand JM, Heaney LG, Lightstone L, Lu N, Murrell DF, Petri M, Rosenbaum JT, Saag KS, Urowitz MB, Winthrop KL, Stone JH. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017 Mar; 76(3):543-546.
  17. Balk LJ, Cruz-Herranz A, Albrecht P, Arnow S, Gelfand JM, Tewarie P, Killestein J, Uitdehaag BM, Petzold A, Green AJ. Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study. J Neurol. 2016 Jul; 263(7):1323-31.
  18. Block VA, Pitsch E, Tahir P, Cree BA, Allen DD, Gelfand JM. Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review. PLoS One. 2016; 11(4):e0154335.
  19. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Hftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Prss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostsy K, Saiz A, Venkatesan A, Vincent A, Wandinger KP, Waters P, Dalmau J. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016 Apr; 15(4):391-404.
  20. Schubert RD, Wood M, Levin MH, Perry A, Gelfand JM. The severe side of the IgG4-related hypertrophic pachymeningitis disease spectrum. Neurol Neuroimmunol Neuroinflamm. 2016 Feb; 3(1):e197.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.